ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL.7, 2012, Pages 38-52

  Hope, W W ^a   Castagnola, E ^b   Groll, A H ^c   Roilides, E ^d   Akova, M ^e   Arendrup, M C ^f   Arikan Akdagli, S ^e   Bassetti, M ^g   Bille, J ^h   Cornely, O A ⁱ   Cuenca Estrella, M ^j   Donnelly, J P ^k   Garbino, J ^l   Herbrecht, R ^m   Jensen, H E ⁿ   Kullberg, B J ^k   Lass Florl C ^o   Lortholary, O ^p,q   Meersseman, W ^r   Petrikkos, G ^s   Richardson, M D ^t   Verweij, P E ^k   Viscoli, C ^u   Ullmann, A J ^v   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e HACETTEPE UNIVERSITY   (Turkey)

^f STATENS SERUM INSTITUT   (Denmark)

^g S Maria Hospital   (Italy)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^m UNIVERSITÉ DE STRASBOURG   (France)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

^o INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^p HÔPITAL NECKER ENFANTS MALADES   (France)

^q INSTITUT PASTEUR   (France)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s UNIVERSITY OF ATHENS   (Greece)

^t UNIVERSITY OF MANCHESTER   (United Kingdom)

^u UNIVERSITY OF GENOA   (Italy)

^v UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Antifungal agents; Candida disease; Children; Europe; Neonates

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; LACTOFERRIN; MICAFUNGIN; MICONAZOLE; NYSTATIN; POSACONAZOLE; VINCRISTINE; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CENTRAL NERVOUS SYSTEM INFECTION; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; EXTREMELY LOW BIRTH WEIGHT; FUNGAL COLONIZATION; HUMAN; INVASIVE CANDIDIASIS; LACTOBACILLUS RHAMNOSUS; LOADING DRUG DOSE; LONG TERM CARE; MENINGOENCEPHALITIS; META ANALYSIS (TOPIC); NEPHROTOXICITY; NEUROTOXICITY; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SECONDARY PREVENTION; SINGLE DRUG DOSE; TREATMENT DURATION; ADOLESCENT; CHILD; DRUG EFFECT; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEWBORN; PEDIATRICS; PRESCHOOL CHILD;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; PEDIATRICS;

EID: 84867702520     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12040     Document Type: Article

References (141)

1. European Medicines Agency. Clinical investigation of medicinal products in the paediatric population note for guidance on clinical investigation of medicinal products in the paediatric population (cpmp/ich/2711/99). 2001. http://www.ema.europa.eu/pdfs/human/ich/271199en.pdf
2. European Medicines Agency. European community. Regulation (ec) no 1901/2006 of the European parliament and of the council of medicinal products for paediatric us, amended by regulation (ec) no 1902/2006. 2006. http://serviziwebunimolit/unimol/allegati/pagine/5762/cecipdf
3. Benjamin DK Jr, Stoll BJ, Fanaroff AA et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22months. Pediatrics 2006; 117: 84-92.
4. Benjamin DK Jr, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003; 112: 634-640.
5. Manzoni P, Jacqz-Aigrain E, Rizzollo S et al. Antifungal prophylaxis in neonates. Early Hum Dev 2011; 87 (Suppl 1): S59-S60.
6. Roilides E. Invasive candidiasis in neonates and children. Early Hum Dev 2011; 87 (Suppl 1): S75-S76.
7. Roilides E, Farmaki E, Evdoridou J et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 2004; 23: 745-750.
8. Pasqualotto AC, De Moraes AB, Zanini RR, Severo LC. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 2007; 28: 799-804.
9. Tragiannidis A, Fegeler W, Rellensmann G et al. Candidaemia in a European paediatric university hospital: a 10-year observational study. Clin Microbiol Infect 2011; 18(2): E27-30.
10. Zaoutis TE, Prasad PA, Localio AR et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51: e38-e45.
11. Roilides E, Kadiltsoglou I, Zahides D, Bibashi E. Invasive candidosis in pediatric patients. Clin Microbiol Infect 1997; 3: 192-197.
12. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39 (Suppl 4): S200-S206.
13. Danziger-Isakov LA, Sweet S, Delamorena M, Huddleston CB, Mendeloff E, Debaun MR. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J 2005; 24: 324-330.
14. Gladdy RA, Richardson SE, Davies HD, Superina RA. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 1999; 5: 16-24.
15. Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010; 26: 1769-1778.
16. Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006; 49: 484-492.
17. Sims ME, Yoo Y, You H, Salminen C, Walther FJ. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988; 5: 33-36.
18. Austin N, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2009; 4: CD003478.
19. Aydemir C, Oguz SS, Dizdar EA et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2010; 96: F164-F168.
20. Violaris K, Carbone T, Bateman D, Olawepo O, Doraiswamy B, LaCorte M. Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. Am J Perinatol 2009; 27: 73-78.
21. Wainer S, Cooper PA, Funk E, Bental RY, Sandler DA, Patel J. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11: 713-716.
22. Manzoni P, Mostert M, Leonessa ML et al. Oral supplementation with lactobacillus casei subspecies rhamnosus prevents enteric colonization by candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735-1742.
23. Manzoni P, Rinaldi M, Cattani S et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302: 1421-1428.
24. Manzoni P, Stolfi I, Messner H et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2011; 129: 116-123.
25. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107: 293-298.
26. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660-1666.
27. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005; 147: 172-179.
28. Manzoni P, Stolfi I, Pugni L et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007; 356: 2483-2495.
29. Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005; 147: 162-165.
30. Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005; 147: 166-171.
31. Manzoni P, Arisio R, Mostert M et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 2006; 117: e22-e32.
32. Uko S, Soghier LM, Vega M et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006; 117: 1243-1252.
33. Aghai ZH, Mudduluru M, Nakhla TA et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006; 26: 550-555.
34. McCrossan BA, McHenry E, O'Neill F, Ong G, Sweet DG. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007; 92: F454-F458.
35. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant candida species. Pediatrics 2008; 121: 703-710.
36. Weitkamp JH, Ozdas A, LaFleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 2008; 28: 405-411.
37. Clerihew L, Austin N, McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review. Arch Dis Child Fetal Neonatal Ed 2008; 93: F198-F200.
38. Kaufman D. Fluconazole prophylaxis decreases the combined outcome of invasive candida infections or mortality in preterm infants. Pediatrics 2008; 122: 1158-1159; author reply 1159.
39. Kaufman DA, Cuff AL, Wamstad JB et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10years of age. J Pediatr 2011; 158: 759-765.
40. Benjamin DK Jr, Stoll BJ, Gantz MG et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126: e865-e873.
41. Cohen-Wolkowiez M, Smith PB, Mangum B et al. Neonatal candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007; 27(2): 97-100.
42. Linder N, Klinger G, Shalit I et al. Treatment of candidaemia in premature infants: comparison of three amphotericin b preparations. J Antimicrob Chemother 2003; 52: 663-667.
43. Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31: 458-463.
44. Starke JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin b in infants and children. J Infect Dis 1987; 155: 766-774.
45. Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin b in experimental candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274-282.
46. Juster-Reicher A, Leibovitz E, Linder N et al. Liposomal amphotericin b (ambisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000; 28: 223-226.
47. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin b in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003; 22: 603-607.
48. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin b for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-826.
49. Weitkamp JH, Poets CF, Sievers R et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin b (ambisome). Infection 1998; 26: 11-15.
50. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin b lipid complex in neonates. Antimicrob Agents Chemother 2005; 49: 5092-5098.
51. Schwarze R, Penk A, Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res 2000; 5: 203-208.
52. Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs. Amphotericin b for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996; 15: 1107-1112.
53. Driessen M, Ellis JB, Muwazi F, De Villiers FP. The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 1997; 17: 263-271.
54. Piper L, Smith PB, Hornik CP et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011; 30: 375-378.
55. Wade KC, Wu D, Kaufman DA et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008; 52: 4043-4049.
56. Heresi GP, Gerstmann DR, Reed MD et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25: 1110-1115.
57. Hope WW, Mickiene D, Petraitis V et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197: 163-171.
58. Hope WW, Smith PB, Arrieta A et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54: 2633-2637.
59. Warn PA, Livermore J, Howard S et al. Anidulafungin for neonatal hematogenous candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother 2011; 52: 230.
60. Cohen-Wolkowiez M, Benjamin DK Jr, Piper L et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011; 89: 702-707.
61. Saez-Llorens X, Macias M, Maiya P et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3months of age. Antimicrob Agents Chemother 2009; 53: 869-875.
62. Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093-1097.
63. Manzar S, Kamat M, Pyati S. Caspofungin for refractory candidemia in neonates. Pediatr Infect Dis J 2006; 25: 282-283.
64. Smith PB, Steinbach WJ, Cotten CM et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007; 27: 127-129.
65. Benjamin DK Jr, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: 227-234.
66. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 2010; 149: 263-272.
67. Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56: 1092-1097.
68. Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic hsct: review of the literature and options for clinical practice. Drugs 2012; 72(5): 685-704
69. Groll AH, Ritter J, Muller FM. [prevention of fungal infections in children and adolescents with cancer]. Klin Padiatr 2001; 213 (Suppl 1): A50-A68.
70. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
71. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
72. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
73. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987-993.
74. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre study group. Eur J Clin Microbiol Infect Dis 1994; 13: 330-337.
75. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43: 1955-1960.
76. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
77. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-713.
78. De Repentigny L, Ratelle J, Leclerc JM et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42: 404-408.
79. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999; 24: 1089-1093.
80. Groll AH, Wood L, Roden M et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 2554-2563.
81. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42: 591-600.
82. Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 21: 4615-4626.
83. Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-5118.
84. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172.
85. Walsh TJ, Driscoll T, Milligan PA et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54: 4116-4123.
86. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-944.
87. Driscoll TA, Frangoul H, Nemecek ER et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother 2011; 55: 5780-5789.
88. Driscoll TA, Yu LC, Frangoul H et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011; 55: 5770-5779.
89. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50: 27-36.
90. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
91. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-4788.
92. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
93. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007; 51: 812-818.
94. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-119.
95. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit 2012; 34: 72-76.
96. Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-3719.
97. Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin (fk463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-3324.
98. Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011; 30: e97-e102.
99. Van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
100. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The canadian fluconazole prophylaxis study group. Clin Infect Dis 1999; 28: 331-340.
101. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
102. Lehrnbecher T, Attarbaschi A, Duerken M et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29: 1043-1045.
103. Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Gimema infection program. Gruppo italiano malattie ematologiche dell' adulto. Clin Infect Dis 1999; 28: 250-255.
104. Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin b in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306-1312.
105. Hong Y, Shaw PJ, Nath CE et al. Population pharmacokinetics of liposomal amphotericin b in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006; 50: 935-942.
106. Kolve H, Ahlke E, Fegeler W, Ritter J, Jurgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin b in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother 2009; 64: 383-387.
107. Mattiuzzi GN, Cortes J, Alvarado G et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 2011; 19: 19-26.
108. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16: 1343-1353.
109. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76: 2357-2362.
110. Maertens JA, Madero L, Reilly AF et al. A randomized, double-blind, multicenter study of caspofungin vs. liposomal amphotericin b for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29(5): 415-420.
111. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal vs. conventional amphotericin b for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
112. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group. N Engl J Med 1999; 340: 764-771.
113. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin vs. liposomal amphotericin b for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
114. Viscoli C, Castagnola E, Van Lint MT et al. Fluconazole vs. amphotericin b as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32A: 814-820.
115. Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole vs. placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
116. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with candida colonization. Crit Care Med 2006; 34: 730-737.
117. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' For discriminating between candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-1633.
118. Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-276.
119. Piarroux R, Grenouillet F, Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-2449.
120. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-758.
121. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
122. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
123. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin b for the treatment of candidemia in patients without neutropenia. Candidemia study group and the national institute. N Engl J Med 1994; 331: 1325-1330.
124. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin b for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
125. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-4545.
126. Zaoutis T, Lehrnbecher T, Groll AH et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009; 28: 1132-1135.
127. Kuse ER, Chetchotisakd P, Da Cunha CA et al. Micafungin vs. liposomal amphotericin b for candidaemia and invasive candidosis: a phase iii randomised double-blind trial. Lancet 2007; 369: 1519-1527.
128. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin vs. fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
129. Benjamin DK Jr, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50: 632-638.
130. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin b lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
131. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin b lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005; 24: 167-174.
132. Nath CE, McLachlan AJ, Shaw PJ, Gunning R, Earl JW. Population pharmacokinetics of amphotericin b in children with malignant diseases. Br J Clin Pharmacol 2001; 52: 671-680.
133. Benson JM, Nahata MC. Pharmacokinetics of amphotericin b in children. Antimicrob Agents Chemother 1989; 33: 1989-1993.
134. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole vs. a regimen of amphotericin b followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
135. Baley JE, Annable WL, Kliegman RM. Candida endophthalmitis in the premature infant. J Pediatr 1981; 98: 458-461.
136. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
137. Molina JR, Serrano J, Sanchez-Garcia J et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 562-567.
138. Mandhaniya S, Swaroop C, Thulkar S et al. Oral voriconazole vs. intravenous low dose amphotericin b for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol 2011; 33: e333-e341.
139. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo vs. fluconazole plus amphotericin b as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-1228.
140. Walsh TJ, Seibel NL, Arndt C et al. Amphotericin b lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18: 702-708.
141. Ullmann AJ, Cornely OA, Donnelly JP et al. ESCMID Diagnostic and Management Guideline for Candida Diseases 2012: Developing European Guidelines in Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2012; 18(Suppl 7): 1-8.